XERS
What one share of Xeris Biopharma Holdings holds
Pharmaceutical Preparations
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
Xeris Biopharma Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.86 |
|---|---|
| Profit | −$0.10 |
| Cash and investments | $0.70 |
| Debt | $1.46 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.48 | −$2.14 | $0.01 | −$1.90 | — | $0.57 |
| 2021 | $0.63 | −$1.55 | $0.01 | −$1.22 | — | $0.76 |
| 2022 | $0.81 | −$0.70 | — | −$0.76 | — | $0.33 |
| 2023 | $1.19 | −$0.45 | — | −$0.34 | — | −$0.05 |
| 2024 | $1.38 | −$0.37 | — | −$0.25 | — | −$0.20 |
| 2025 | $1.69 | $0.00 | — | $0.17 | — | $0.08 |